[{"address1": "60 Jubilee Avenue", "address2": "Milton Park", "city": "Abingdon", "zip": "OX14 4RX", "country": "United Kingdom", "phone": "44 12 3543 0000", "website": "https://www.adaptimmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has a strategic collaboration with Gal\u00e1pagos for a clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Gal\u00e1pagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; a collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.", "fullTimeEmployees": 506, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christopher James Hill ACA, BA (Hons)", "age": 45, "title": "CEO, CFO, Secretary & Director", "yearBorn": 1980, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Helen Katrina Tayton-Martin MBA, Ph.D.", "age": 58, "title": "Co-Founder", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 677404, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juli P. Miller Ph.D.", "title": "VP of Corporate Affairs & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dana  Lynch", "title": "Senior Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kimberly  Freeman", "title": "Vice President of Commercial Planning", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Laura  Gunn", "title": "Vice President of Medical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.028, "open": 0.028, "dayLow": 0.028, "dayHigh": 0.028, "regularMarketPreviousClose": 0.028, "regularMarketOpen": 0.028, "regularMarketDayLow": 0.028, "regularMarketDayHigh": 0.028, "payoutRatio": 0.0, "beta": 2.466, "volume": 117624, "regularMarketVolume": 117624, "averageVolume": 1823153, "averageVolume10days": 426690, "averageDailyVolume10Day": 426690, "bid": 0.0264, "ask": 0.0278, "bidSize": 42023, "askSize": 30000, "marketCap": 6891341, "fiftyTwoWeekLow": 0.001, "fiftyTwoWeekHigh": 0.62, "allTimeHigh": 21.57, "allTimeLow": 0.001, "priceToSalesTrailing12Months": 0.10588217, "fiftyDayAverage": 0.0341, "twoHundredDayAverage": 0.12805, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 40112404, "profitMargins": -2.6082199, "floatShares": 1579590860, "sharesOutstanding": 265051591, "sharesShort": 31376776, "sharesShortPriorMonth": 23052335, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.1184, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.00686, "shortRatio": 0.19, "shortPercentOfFloat": 0.1434, "impliedSharesOutstanding": 265051597, "bookValue": -0.268, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -169756000, "trailingEps": -0.66, "enterpriseToRevenue": 0.616, "enterpriseToEbitda": -0.292, "52WeekChange": -0.9484536, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 0.026, "targetHighPrice": 1.5, "targetLowPrice": 1.5, "targetMeanPrice": 1.5, "targetMedianPrice": 1.5, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 26061000, "totalCashPerShare": 0.016, "ebitda": -137240992, "totalDebt": 48680000, "quickRatio": 1.067, "currentRatio": 1.516, "totalRevenue": 65085000, "revenuePerShare": 0.252, "returnOnAssets": -0.40862998, "returnOnEquity": -13.410971, "grossProfits": -63606000, "freeCashflow": -123189752, "operatingCashflow": -190027008, "revenueGrowth": -0.893, "grossMargins": -0.97727996, "ebitdaMargins": -2.10864, "operatingMargins": -2.21452, "financialCurrency": "USD", "symbol": "ADAPY", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "regularMarketPrice": 0.026, "shortName": "Adaptimmune Therapeutics plc", "longName": "Adaptimmune Therapeutics plc", "exchange": "PNK", "messageBoardId": "finmb_113495056", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -7.142858, "marketState": "CLOSED", "corporateActions": [], "regularMarketTime": 1770325200, "epsTrailingTwelveMonths": -0.66, "fiftyDayAverageChange": -0.008099999, "fiftyDayAverageChangePercent": -0.23753664, "twoHundredDayAverageChange": -0.10205, "twoHundredDayAverageChangePercent": -0.79695433, "priceToBook": -0.09701493, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1430919000000, "regularMarketChange": -0.0020000003, "regularMarketDayRange": "0.028 - 0.028", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 1823153, "fiftyTwoWeekLowChange": 0.025, "fiftyTwoWeekLowChangePercent": 25.0, "fiftyTwoWeekRange": "0.001 - 0.62", "fiftyTwoWeekHighChange": -0.594, "fiftyTwoWeekHighChangePercent": -0.9580645, "fiftyTwoWeekChangePercent": -94.84536, "earningsTimestampStart": 1771880400, "earningsTimestampEnd": 1771880400, "isEarningsDateEstimate": true, "displayName": "Adaptimmune Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]